share_log

Short Interest in Artemis Therapeutics Inc. (OTCMKTS:ATMS) Drops By 15.4%

Defense World ·  Aug 15, 2022 03:21

Artemis Therapeutics Inc. (OTCMKTS:ATMS – Get Rating) saw a significant decrease in short interest in July. As of July 31st, there was short interest totalling 1,100 shares, a decrease of 15.4% from the July 15th total of 1,300 shares. Based on an average daily trading volume, of 500 shares, the short-interest ratio is presently 2.2 days.

Artemis Therapeutics Trading Down 49.4 %

Shares of OTCMKTS:ATMS opened at $0.91 on Monday. The company has a fifty day moving average of $3.34 and a 200-day moving average of $2.19. Artemis Therapeutics has a 52-week low of $0.55 and a 52-week high of $5.00.

Get Artemis Therapeutics alerts:

Artemis Therapeutics (OTCMKTS:ATMS – Get Rating) last posted its quarterly earnings data on Monday, May 23rd. The company reported ($0.01) earnings per share for the quarter.

About Artemis Therapeutics

(Get Rating)

Artemis Therapeutics Inc does not have significant operations. Previously, it was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company is based in New York, New York. Artemis Therapeutics Inc is a subsidiary of Tonak Ltd.

Further Reading

  • Get a free copy of the StockNews.com research report on Artemis Therapeutics (ATMS)
  • Here is a Simple 4 Stock Portfolio that Can Outperform the Market
  • Is AMC Entertainment Pulling a Fast One on the APEs?
  • Here's How the Inflation Reduction Act Energizes Power Stock
  • 2 Important Retail Stock Battles to Watch
  • MarketBeat: Week in Review 8/8 – 8/12

Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment